Bioanalytical Systems (NASDAQ:BASI) Stock Crosses Above 200-Day Moving Average of $3.02

Shares of Bioanalytical Systems, Inc. (NASDAQ:BASI) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.02 and traded as high as $4.65. Bioanalytical Systems shares last traded at $4.52, with a volume of 24,848 shares changing hands.

Separately, ValuEngine downgraded Bioanalytical Systems from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd.

The firm has a 50 day simple moving average of $4.59 and a two-hundred day simple moving average of $3.02. The company has a quick ratio of 0.61, a current ratio of 0.67 and a debt-to-equity ratio of 1.19.

In other news, CEO Robert Jr. Leasure bought 11,500 shares of Bioanalytical Systems stock in a transaction dated Wednesday, September 4th. The stock was bought at an average price of $3.15 per share, for a total transaction of $36,225.00. Following the purchase, the chief executive officer now owns 138,119 shares of the company’s stock, valued at $435,074.85. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Wendy Perrow bought 10,000 shares of Bioanalytical Systems stock in a transaction dated Tuesday, September 10th. The stock was purchased at an average price of $3.62 per share, with a total value of $36,200.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $36,200. The disclosure for this purchase can be found here. Insiders acquired a total of 71,846 shares of company stock worth $256,567 over the last quarter. Company insiders own 7.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of BASI. Essex Investment Management Co. LLC acquired a new stake in Bioanalytical Systems in the third quarter valued at about $340,000. Virtu Financial LLC purchased a new stake in Bioanalytical Systems in the 3rd quarter valued at approximately $97,000. Finally, Renaissance Technologies LLC boosted its holdings in Bioanalytical Systems by 7.7% in the 2nd quarter. Renaissance Technologies LLC now owns 253,001 shares of the company’s stock valued at $506,000 after purchasing an additional 18,120 shares in the last quarter. 8.18% of the stock is owned by hedge funds and other institutional investors.

About Bioanalytical Systems (NASDAQ:BASI)

Bioanalytical Systems, Inc provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products.

Recommended Story: The basics of gap trading strategies

Receive News & Ratings for Bioanalytical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems and related companies with MarketBeat.com's FREE daily email newsletter.